Business ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Market Competition Obesity Treatments Licensing Agreements Market Access Oncology Market Trends Clinical Research Obesity Drugs

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

The readout underscores a clean cardiac safety profile, preserving the timeline for full Part D data in Q2 2026.

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

FDA Qualifies First AI Tool for MASH Drug Trials

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

Bayer’s Asundexian Cuts Recurrent Stroke Risk in Phase III Without More Major Bleeding

Eli Lilly Hits $1 Trillion Valuation on GLP‑1 Weight‑Loss Boom

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs

Munich AI Startup Cellbyte Raises $2.75 Million Seed to Speed Drug Launches

Novo Nordisk Foundation Installs Lars Rebien Sørensen as Chair After Shareholder Vote

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays